Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy
- PMID: 24841650
- DOI: 10.4238/2014.April.25.3
Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy
Abstract
We conducted a comprehensive study to investigate the role of genes involved in metabolic and transport pathways in response to chemotherapy and clinical outcome of osteosarcoma patients. Genotyping of seven gene polymorphisms was performed on a 384-well plate format on the Sequenom MassARRAY platform in 162 patients with osteosarcoma. We studied the correlation of the seven gene polymorphisms with response to chemotherapy and clinical outcome of patients. Individuals with the ABCB1 TT genotype had a higher probability of responding poorly to chemotherapy, indicated by an odds ratio (OR) of 2.64 (95%CI=1.04-6.83). Similarly, the genotype of GSTP1 GG was significantly associated with improved responses to chemotherapy, indicated by an OR of 3.33 (95%CI=1.26-8.99). The ABCB1 TT and GSTP1 GG genotypes were significantly associated with a shorter overall survival (OS). Our study found that two gene polymorphisms in two transporter genes and one Phase II metabolism enzymes are associated with response to chemotherapy and OS in osteosarcoma patients, suggesting the potential of the two gene polymorphisms as prognostic biomarkers for osteosarcoma.
Similar articles
-
Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.Tumour Biol. 2014 Oct;35(10):9897-904. doi: 10.1007/s13277-014-1917-x. Epub 2014 Jul 5. Tumour Biol. 2014. PMID: 24996541
-
Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.Asian Pac J Cancer Prev. 2013;14(8):4595-8. doi: 10.7314/apjcp.2013.14.8.4595. Asian Pac J Cancer Prev. 2013. PMID: 24083708
-
Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Cancer. 2012 Apr 1;118(7):1856-67. doi: 10.1002/cncr.26472. Epub 2011 Sep 1. Cancer. 2012. PMID: 21887680
-
Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance.Exp Mol Pathol. 2019 Feb;106:63-77. doi: 10.1016/j.yexmp.2018.12.002. Epub 2018 Dec 7. Exp Mol Pathol. 2019. PMID: 30528563 Review.
-
Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Expert Opin Drug Metab Toxicol. 2015;11(9):1449-63. doi: 10.1517/17425255.2015.1060220. Epub 2015 Jun 25. Expert Opin Drug Metab Toxicol. 2015. PMID: 26095223 Review.
Cited by
-
ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.Int J Clin Exp Med. 2015 Jan 15;8(1):265-72. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25784996 Free PMC article.
-
Computational Analysis of MDR1 Variants Predicts Effect on Cancer Cells via their Effect on mRNA Folding.PLoS Comput Biol. 2024 Dec 26;20(12):e1012685. doi: 10.1371/journal.pcbi.1012685. eCollection 2024 Dec. PLoS Comput Biol. 2024. PMID: 39724131 Free PMC article.
-
Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.Tumour Biol. 2015 Mar;36(3):1329-38. doi: 10.1007/s13277-015-3181-0. Epub 2015 Feb 11. Tumour Biol. 2015. PMID: 25666750 Review.
-
Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.Onco Targets Ther. 2015 Jul 23;8:1835-42. doi: 10.2147/OTT.S81115. eCollection 2015. Onco Targets Ther. 2015. PMID: 26229491 Free PMC article.
-
Genetic variants associated with osteosarcoma risk: a systematic review and meta-analysis.Sci Rep. 2024 Feb 15;14(1):3828. doi: 10.1038/s41598-024-53802-w. Sci Rep. 2024. PMID: 38360742 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous